Stockreport

Week In Review: ImmuneOnco Out-Licenses 2 Antibodies In $2 Billion Deal [Seeking Alpha]

Instil Bio, Inc.  (TIL) 
NASDAQ:AMEX Investor Relations: nasdaq.com/symbol/til
PDF Summary ImmuneOnco Biopharma out-licensed global rites (ex-China) for two of its antibodies to Instil Bio of Dallas, Texas. Otsuka Pharmaceutical acquired Jnana The [Read more]